Investment Analysts’ Recent Ratings Updates for Option Care Health (OPCH)

A number of research firms have changed their ratings and price targets for Option Care Health (NASDAQ: OPCH):

• 1/16/2026 – Option Care Health had its price target raised by analysts at Barrington Research from $38.00 to $42.00. They now have an “outperform” rating on the stock.
• 1/13/2026 – Option Care Health had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $37.00 price target on the stock.
• 1/13/2026 – Option Care Health was given a new $40.00 price target on by analysts at Truist Financial Corporation.
• 1/13/2026 – Option Care Health had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 1/13/2026 – Option Care Health had its price target raised by analysts at Morgan Stanley from $35.00 to $38.00. They now have an “overweight” rating on the stock.
• 1/13/2026 – Option Care Health had its “market outperform” rating reaffirmed by analysts at Citizens Jmp. They now have a $38.00 price target on the stock, up previously from $36.00.
• 1/10/2026 – Option Care Health was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/29/2025 – Option Care Health had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Option Care Health had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Option Care Health had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/14/2025 – Option Care Health was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/11/2025 – Option Care Health was upgraded by analysts at Stephens to a “strong-buy” rating.
• 12/10/2025 – Option Care Health is now covered by analysts at Stephens. They set an “overweight” rating and a $40.00 price target on the stock.
• 12/9/2025 – Option Care Health had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $31.00 to $36.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Option Care Health had its price target raised by analysts at Bank of America Corporation from $32.00 to $35.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Option Care Health had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Option Care Health was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/25/2025 – Option Care Health had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 38,000 shares of the stock in a transaction on Monday, November 3rd. The shares were purchased at an average cost of $25.98 per share, with a total value of $987,240.00. Following the completion of the transaction, the director directly owned 413,390 shares of the company’s stock, valued at $10,739,872.20. This represents a 10.12% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.64% of the company’s stock.

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.